Table of Contents Table of Contents
Previous Page  538 / 812 Next Page
Information
Show Menu
Previous Page 538 / 812 Next Page
Page Background

S534

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV576

Cognitive functioning in patients

suffering from anorexia nervosa: A

longitudinal study

G. Rekkedal

, U. Kessler , Y. Danielsen , S. Frostad

Haukeland University Hospital, Clinic for psychosomatic medicine,

Bergen, Norway

Corresponding author.

Introduction

The majority of research concerning cognitive func-

tioning in eating disorders has focused on the symptomatic phase

of illness in patients suffering from Anorexia Nervosa. There is a

lack of longitudinal studies focusing on the possible effects of cog-

nitive functioning on treatment outcome. Further, only a subgroup

of studies control for the effects of depression and depressive symp-

toms in this field of research.

Objective

The main objective of the present study is to examine

cognitive functioning in patients suffering Anorexia in a longitu-

dinal perspective. Secondly, to examine and clarify the effects of

depression on cognitive functioning in patients suffering Anorexia.

Thirdly, the aim is to investigate cognitive functioning in Anorexia

as a possible predictor for treatment outcome and retention.

Methods

Patients aged

16 years diagnosed with Anorexia Ner-

vosa, admitted to outpatient treatment (CBT-E) at Section for

Eating Disorders, Haukeland University Hospital, will be recruited

to the study. A healthy control group and a comparison group of

patients diagnosed with first episode major depressive disorder

will also be included. The neuropsychological assessment consists

of a comprehensive test battery including well-established neu-

ropsychological tests known to have good psychometric properties.

Depressive symptoms will be measured by the Montgomery Aas-

berg Depression Rating scale and eating disorder symptoms will

be assessed with the EDE-Q. The neuropsychological assessment

will be performed three times during the study: before treatment,

post treatment and one year after discharge. The assessment will

be performed at the Institute of biological and medical psychology,

Section of clinical neuropsychology, University of Bergen.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1561

EV577

Perfectionism, a transdiagnostic

construct in eating disorders

T. Rodriguez Cano

1 ,

, L. Beato Fernandez

1

, B. Mata Saenz

1

,

L. Rojo Moreno

2

, F.J. Vaz Leal

3

1

Hospital General Ciudad Real, Psychiatry, Ciudad Real, Spain

2

Universidad de Valencia. HUiP la Fe, Professor of Psychiatry,

Valencia, Spain

3

University of Extremadura Medical School Head. Mental Health and

Eating Disorder Unit. University Hospital Network Badajoz, Professor

of Psychiatry, Badajoz, Spain

Corresponding author.

Introduction

Perfectionism is considered a multidimensional key

risk factor for Eating Disorders (EDs). There are discrepancies

regarding if it is mainly associated to Anorexia nervosa (AN) but

not to other EDs.

Objectives

To study if Perfectionism is not only related with AN,

but it is present in all EDs and associated withmore transdiagnostic

attitudes and behaviors.

Aims

To see if there were significant differences among EDs sub-

groups concerning Perfectionism and to study which abnormal

eating attitudes were more associated with this trait.

Methods

Participants were 151 outpatients with EDs. DSM-

IVTR diagnoses were: 44 (29.1%) Anorexia Nervosa (AN), 55

(36.4%) Bulimia Nervosa (BN) and 52 (34.4%) Eating Disorders not

Otherwise Specified (EDNOS). Perfectionism was assessed with

the Edinburg Investigatory Test (EDI-2) subscale; general psy-

chopathology with the Beck Depression Inventory (BDI), State

and Trait Anxiety Inventory (STAI), Rosenberg Self-Esteem Ques-

tionnaire (RSE). Eating psychopathology was measured with the

Bulimic Investigatory Test (BITE), Eating Attitude Test (EAT-40),

EDI-2 and the Body Shape Questionnaire (BSQ).

Results

No significant differences were found regarding Perfec-

tionism among the three groups. Body dissatisfaction was the

variable most associated with Perfectionism (

ˇ

= 0.330,

F

= 14.2,

P

< 0.001, 10.9% of the variance) adjusting for general and eating

psychopathology. Ascetism and Interoceptive awareness were the

EDI-2 subscales most associated with Perfectionism.

Conclusions

The findings confirm that Perfectionism is present

in all EDs and there is a relationship between body dissatisfaction

and Perfectionism. Interplay has been suggested between these two

factors for the development of EDs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1562

EV578

A review on pharmacotherapy of

eating disorders

E. Roohi

, F. Hashemian

Faculty of Pharmacy, Islamic Azad University, Pharmaceutical

Sciences Branch, Department of Clinical Pharmacy, Tehran, Iran

Corresponding author.

Introduction

Eating disorders are identified as chronic debilitat-

ing psychiatric illnesses, which are refractory to treatment in many

patients. The mortality rate associated with eating disorders is

known to be the highest of any psychiatric disorder.

Aims

The aim of the present article was to review pharma-

cological treatments available for patients with eating disorders.

Moreover, mechanism of action, dosages and algorithm of use of

the available treatments were discussed. Some optional new treat-

ments undergoing clinical trials were also mentioned.

Methods

Studies were identified by searching electronic

databases of Medline, Cochrane Library, and Clinical Trial Regis-

ters. All eligible studies investigating efficacy and safety of the

pharmacological treatments of patients with eating disorders

conducted between 2000 and 2015 were included in the present

article.

Results

Current pharmacotherapies include Selective Serotonin

Reuptake Inhibitors (SSRIs), atypical antipsychotics, mood stabi-

lizers, androgen receptor antagonists, serotonin antagonists and

antihistamines. However, level of evidence for pharmacotherapy

of each category of eating disorders are not the same.

Conclusions

The use of pharmacotherapy integrated with behav-

ioral and cognitive therapies are recommended. There are still gaps

in the knowledge regarding pharmacotherapy of eating disorders.

Development of agentswithmore efficacy and better safety profiles

are needed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1563

EV579

Eating disorders. Review of current

treatment options for anorexia

nervosa, focused on psychotherapy

and pharmacological treatment

B. Sánchez Sánchez

1 ,

, P. Mu˜noz-Calero Franco

1

,

N. Rodriguez Criado

1

, J.F. Cruz Fourcade

1

, R. Martín Aragón

1

,

S. Bravo Herrero

1

, M. García-Poggio Fernández

1

,

M. Gil-Eliche Moreno

1

, A. De Cos Milas

2

,

N. Chinchurreta de Lora

2